Financial Performance - The company's operating revenue for 2023 was ¥579,334,659.15, a decrease of 4.56% compared to ¥606,992,213.55 in 2022[22]. - The net profit attributable to shareholders for 2023 was -¥93,073,691.42, reflecting a 2.77% increase in losses from -¥90,563,424.65 in 2022[22]. - The cash flow from operating activities showed a significant decline, with a net outflow of -¥24,561,754.07 in 2023 compared to a positive inflow of ¥89,184,806.94 in 2022, marking a 127.54% decrease[22]. - The basic and diluted earnings per share for 2023 were both -¥0.2927, a 2.77% increase in losses from -¥0.2848 in 2022[22]. - Total assets at the end of 2023 were ¥2,810,906,249.36, down 5.35% from ¥2,969,827,475.68 at the end of 2022[22]. - The net assets attributable to shareholders decreased by 4.18% to ¥2,091,482,920.76 at the end of 2023 from ¥2,182,776,737.97 at the end of 2022[22]. - The company reported a total revenue of ¥540,558,184.57 after deducting other income for 2023, compared to ¥577,229,323.41 in 2022, indicating a decline of 6.35%[22]. - The company reported non-operating income of ¥6,041,782.61 in 2023, down from ¥15,102,067.30 in 2022, indicating a decrease of 59.93%[28]. - The company reported a total revenue of 10,029,593.97 in the current period, compared to 28,373,646.97 and 61,832,223.69 in the previous periods, indicating a significant decline[30]. - The company reported an operating loss of CNY -93,573,002.73, which is an increase in loss of 10.47% year-on-year[58]. - The company’s total assets as of December 31, 2023, were CNY 2,810,906,249.36, a decrease of 5.38% from the beginning of the year[59]. - The company’s equity attributable to shareholders was CNY 2,091,482,920.76, down 4.18% from the beginning of the year[59]. - The company’s asset-liability ratio stood at 25.45%[59]. - The company achieved a total revenue of CNY 579,334,659.15, a decrease of 4.56% compared to CNY 606,992,213.55 in 2022[63]. - The pharmaceutical manufacturing segment generated ¥523,420,449.08, accounting for 90.35% of total revenue, down 8.70% from the previous year[63]. - The revenue from pharmaceutical distribution surged by 334.26% to ¥17,137,735.49, representing 2.96% of total revenue[63]. - The gross profit margin for the pharmaceutical manufacturing sector was 47.42%, a decrease of 9.90% year-on-year[65]. - The total operating costs rose by 16.30% to ¥306,567,611, with the pharmaceutical manufacturing costs accounting for 89.77% of total costs[69]. - The company reported a significant increase in sales volume for small volume injections, which rose by 18.99% to 19,491,000 units sold[67]. - The company reported a net profit margin of 12%, reflecting improved operational efficiency and cost management strategies[147]. Corporate Governance - The company maintains compliance with the Company Law and Securities Law, ensuring proper governance and protection of minority shareholders' rights[126]. - The company has adopted a combination of on-site meetings and online voting for shareholder meetings to ensure equal treatment of all shareholders[126]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[130]. - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[130]. - The company has implemented a "Quality Return Double Improvement" action plan, although specific details were not disclosed[124]. - The company has established a complete governance structure and decision-making procedures to mitigate operational risks[169]. - The company has a structured approach to evaluating the performance of its directors and senior management for remuneration purposes[150]. - The company has implemented strict internal control measures to enhance operational efficiency and risk management[61]. - The company has established a performance evaluation mechanism to enhance employee competitiveness while ensuring their legal rights[163]. - The company has a strategy in place to lock shares for investor compensation arrangements in case of legal violations[196]. - The company has maintained a commitment to legal compliance and has been fulfilling its obligations since November 2020[196]. - The company has not faced any administrative penalties or disciplinary actions related to the securities market in the last five years[196]. - The company has established a debt restructuring agreement with its controlling shareholder to address financial irregularities[127]. - The company has actively communicated with investors and ensured transparency in its governance practices[126]. Research and Development - The company has established a research institute that focuses on innovative drugs, improved new drugs, and deep development of traditional Chinese medicine[42]. - The company is committed to innovation in drug development, aligning with national strategies to improve healthcare and pharmaceutical services[35]. - The company will continue to increase R&D investment in traditional Chinese medicine and chemical drugs, focusing on high-end products and optimizing existing products[107]. - The R&D investment as a percentage of operating income was 5.34%, down from 5.65% in the previous year[77]. - Research and development expenses decreased by 9.79% to ¥30,916,051.19, reflecting a reduction in project investments and personnel[77]. - The number of R&D personnel decreased by 8.45% to 65, with a notable reduction in the 30-40 age group by 38.46%[77]. - The R&D expenditure increased by 30% year-over-year, totaling 150 million yuan, to support innovation and product development[198]. Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings in response to the growing demand in the pharmaceutical sector[33]. - The company plans to expand its market presence by targeting hospitals and pharmacies, increasing product accessibility, and collaborating with provincial and county-level distributors[110]. - The company is positioned to benefit from the ongoing reforms in the pharmaceutical industry, which aim to enhance the quality and efficiency of healthcare services[34]. - The company is actively involved in the development of traditional Chinese medicine, with policies supporting its growth and modernization[36]. - The company is exploring new technologies for wastewater treatment to improve efficiency and compliance[179]. - The company aims to expand its market presence while adhering to strict environmental regulations[179]. Environmental Compliance - The company adheres to multiple environmental protection laws and standards, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[176]. - The company reported no significant defects in non-financial reporting as per the internal control audit[173]. - The company has implemented strict compliance with environmental impact assessment requirements for all construction projects[176]. - The company has not reported any instances of exceeding the permitted discharge limits for pollutants[177]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[176]. - The company has established a self-monitoring plan for pollutants, which includes automatic monitoring and manual testing, with data reported to the national pollution permit management information platform[182]. - The company has implemented emergency response plans for environmental incidents, including regular drills to enhance preparedness[182]. - The company plans to enhance its wastewater management strategies to further reduce environmental impact[179]. - The company is committed to maintaining compliance with environmental standards and improving wastewater treatment processes[179]. Legal Issues - The company received a ruling of not guilty from the Chongqing First Intermediate People's Court on December 29, 2023, regarding the bribery charges[119]. - The controlling shareholder, Liu Qun, was ordered to repay a total of RMB 121.474926 million for embezzlement and misappropriation of funds, which was fully repaid by April 8, 2021[121]. - The company has faced significant legal challenges, including a retrial of bribery charges, which could impact its future operations[119]. - The company reported a legal ruling of not guilty regarding bribery charges, which was confirmed by the Chongqing First Intermediate People's Court in December 2023[194]. - The company has not encountered any major issues in the integration of subsidiaries during the reporting period[170]. - The company has committed to compliance and has not been under investigation by judicial authorities or the China Securities Regulatory Commission[196]. Employee Management - The total number of employees at the end of the reporting period was 1,289, with 550 in the parent company and 505 in major subsidiaries[161]. - The professional composition of employees included 749 production personnel, 125 sales personnel, 65 technical personnel, and 31 financial personnel[161]. - The educational background of employees showed that 859 had a vocational education or below, 241 had an associate degree, 181 had a bachelor's degree, and 8 had a master's degree[161]. - The company maintained a fair and transparent salary policy, adhering to local average wages and economic performance for salary distribution[162]. - The company has a structured training system in place, focusing on internal career development and professional skill enhancement for employees[164]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.29 million[151]. - The remuneration for the financial director was CNY 365,300, while the supervisor's remuneration was CNY 135,500[151]. - The total remuneration for the independent directors was CNY 144,000 collectively[151]. Investment and Fundraising - The company raised a total of RMB 118,561.00 million through the issuance of 53 million shares at a price of RMB 22.37 per share, with a net amount of RMB 107,879.07 million after deducting issuance costs[97]. - As of December 31, 2023, the company has unused raised funds totaling RMB 5,681.47 million, which includes RMB 3,000.00 million in structured deposits and RMB 2,681.47 million in the special account[97]. - The company has invested RMB 1,435.83 million into fundraising projects, with a cumulative investment of RMB 75,115.00 million[99]. - The company has committed a total of RMB 107,879 million to various investment projects, with RMB 79,869.32 million already invested[99]. - The company utilized RMB 3,000.00 million of idle raised funds for purchasing structured deposits[97]. - The company has not experienced any significant changes in the use of raised funds or project progress[99]. - The company has successfully completed the non-PVC soft bag large capacity injection project with a 100% completion status[99]. - The company utilized RMB 30 million of idle fundraising to temporarily supplement working capital, with a usage period not exceeding twelve months[101].

关于公司部分资金被扣划的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、公司部分资金被扣划的情况概述 证券代码：002872 证券简称：ST 天圣 公告编号：2024-014 天圣制药集团股份有限公司 四、风险提示 天圣制药集团股份有限公司（以下简称"公司"或"天圣制药"）于 2024 年 4 月 9 日披露了《关于公司部分资金被扣划的公告》（公告编号：2024-012 号）。经公司向银行初步了解，因原告帅培清、王太国、郑守国与被告重庆新 美药业有限公司（以下简称"新美药业"）、天圣制药、陈谊、冯谊的民间借 贷纠纷涉及的相关诉讼事项，法院扣划了公司银行账户资金合计 354.9245 万元， 其中公司募集资金账户重庆农村商业银行股份有限公司江北支行（以下简称 "农商行江北支行"）被扣划募集资金 77.0700万元。具体内容详见公司已披露 的相关公告。 法律措施维护公司及广大投资者的合法权益。另外，公司将尽快启动向陈谊、 冯谊个人的追偿程序。 三、本次资金被扣划对公司的影响 1、本次被扣划资金的银行账户非公司日常经营使用的主要账户，也不涉及 公司基本 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-015 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易被实施其他风险警示。公司于 2019 年 6 月 5 日披露了《关于公司股票交易被实行其他风险警示的公告》；并 分别于 2019 年 7 月 5 日、2019 年 8 月 3 日、2019 年 9 月 5 日、2019 年 10 月 9 日、2019 年 11 月 5 日、2019 年 12 月 5 日、2020 年 1 月 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"或"天圣制药"）于 2023 年 4 月 25 日召开的第五届董事会第十三次会议、第五届监事会第十次会议及 2023 年 5 月 19 日召开的 2022 年度股东大会审议通过了《关于续聘公司 2023 年 度审计机构的议案》，同意继续聘请北京兴华会计师事务所（特殊普通合伙） 为公司 2023 年度财务和内部控制审计机构。具体内容详见公司于 2023 年 04 月 27 日披露的《关于续聘公司 2023 年度审计机构的公告》（公告编号：2023- 023）。 公司近日收到北京兴华会计师事务所（特殊普通合伙）发来的《关于变更 签字注册会计师的告知函》，现将具体情况公告如下： 一、本次变更签字注册会计师的情况 证券代码：002872 证券简称：ST 天圣 公告编号：2024-013 天圣制药集团股份有限公司 关于变更签字注册会计师的公告 北京兴华会计师事务所（特殊普通合伙）作为公司 2023 年度财务报表和 2023 年末财务报告内部控制的审计机构，原委派罗曼和陈敬波作为公司 ...

华西证券股份有限公司 关于天圣制药集团股份有限公司 部分募集资金被划扣的专项核查意见 E 华西证券股份有限公司（以下简称"华西证券"或"保荐人"）作为天圣制 药集团股份有限公司（以下简称"公司"）首次公开发行股票并上市的保荐人， 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第2号——上市公 司募集资金管理和使用的监管要求》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关规定， 对公司部分募集资金被划扣事项进行了核查，具体情况如下： 一、公司募集资金基本情况 经中国证券监督管理委员会《关于核准天圣制药集团股份有限公司首次公开 发行股票的批复》（证监许可〔2017〕620号）的核准，公司首次公开发行人民 币普通股5,300.00万股，每股发行价格22.37元，募集资金总额118,561.00万元，扣 除各项发行费用后，募集资金净额为107,879.07万元。前述募集资金已全部到位， 经由四川华信（集团）会计师事务所（特殊普通合伙）审验，并出具《验资报告》 （川华信验（2017）41号）。公司按规定设立了相关募集资金专户，前述募集资 金已全部存放于 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-012 天圣制药集团股份有限公司 关于公司部分资金被扣划的公告 鉴于法院作出的（2023）渝01民终11949号、（2023）渝01民终3798号、 （2023）渝 01 民终 3801 号民事判决书已发生法律效力，帅培清、王太国、郑 守国向法院申请强制执行，扣划了公司部分资金。 2、上述（2023）渝 01民终 11949号民事判决书涉及的诉讼判决情况如下： 铜梁区人民法院经开庭审理后作出（2022）渝 0151 民初 5075 号民事判决，一 审判决新美药业偿还王太国、帅培清借款本金 84.39万元及相应利息，公司、陈 谊、冯谊对上述债务承担连带清偿责任。公司不服一审判决向重庆市第一中级 人民法院提起上诉，重庆市第一中级人民法院作出（2023）渝 01 民终 11949 号 判决，二审判决驳回上诉，维持原判。 公司正在积极与法院沟通（2023）渝 01 民终 3798 号、（2023）渝 01 民终 3801 号民事判决书涉及的本次被扣划资金的情况。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-011 天圣制药集团股份有限公司 关于为全资子公司向银行申请授信提供 担保及反担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 （一）本次担保及反担保情况概述 湖北省十堰市为充分发挥财政资金的杠杆功能，助力制造业技术改造和转型 升级，十堰市财政部对辖区内符合条件的企业按照贷款金额的年化利率 2%标准 贴息，天圣制药集团股份有限公司（以下简称"公司"或"天圣制药"）之全资 子公司湖北天圣药业有限公司（以下简称"湖北天圣"）符合申请条件，因经营 需要拟向中国农业银行股份有限公司十堰茅箭支行（以下简称"农行茅箭支行"） 申请授信 1,000 万元，借款期限 2 年。公司为本次授信提供担保金额不超过 1,000 万元，具体的担保及反担保情况如下： 1、天圣制药、十堰融资担保集团有限公司（以下简称"十堰融资"）向农 行茅箭支行提供连带责任保证担保； 2、天圣制药向十堰融资提供连带责任保证反担保； 3、公司全资子公司湖北天圣清大中药材有限公司以位于茅箭区（白浪）白 浪街办白浪东路 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-010 天圣制药集团股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 天圣制药集团股份有限公司（以下称"公司"）第六届董事会第三次会议 于 2024 年 3 月 21 日以通讯方式召开。2024 年 3 月 20 日，以电话及电子邮件的 通知方式发出会议通知。 二、董事会会议审议情况 审议通过了《关于为全资子公司向银行申请授信提供担保及反担保的议案》 董事会认为：本次公司为全资子公司向银行申请授信提供担保及反担保事 项是为满足全资子公司日常经营及业务发展需要，本次被担保对象为公司合并 报表范围内的全资子公司，公司能够充分了解其经营情况，对日常经营具有控 制权，有能力对经营管理风险进行控制，整体风险在可控制范围内。虽然湖北 天圣未提供反担保，但公司对其有绝对的控制权，风险均处于公司有效控制下， 不会损害上市公司利益，不会对公司财务状况和经营成果产生重大影响，不会 影响公司持续经营能力，不会损害公司及全体股东的利益。因此，同意公司为 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）于近日获悉控股股东刘 群先生对所持有本公司的部分股份办理了股权质押业务，具体事项如下： 证券代码：002872 证券简称：ST 天圣 公告编号：2024-008 天圣制药集团股份有限公司 关于公司控股股东部分股份质押的公告 1 一、股东股份质押的基本情况 刘群先生此次股份质押是为公司向重庆三峡银行股份有限公司渝中支行 （以下简称"三峡银行渝中支行"）申请授信提供担保。本次质押基本情况如 下： | | 是否为控 | 本次质 | | 占公司 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 押数量 | 占其所 | | 是否为 | 是否为 | 质押起 | 质押到 | | 质押用 | | | 第一大股 | | 持股份 | 总股本 | | 补充质 | | | 质权人 | | | 名称 | | （万 | | | 限售股 | | 始日 | 期日 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2024-005 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易被实施其他风险警示。公司于 2019 年 6 月 5 日披露了《关于公司股票交易被实行其他风险警示的公告》；并 分别于 2019 年 7 月 5 日、2019 年 8 月 3 日、2019 年 9 月 5 日、2019 年 10 月 9 日、2019 年 11 月 5 日、2019 年 12 月 5 日、2020 年 1 月 7 日、2020年 2 月 5日、 2 ...